ライフサイエンスコーパス: mitogen-activated protein kinase

1 efective in activating PAK3 as well as MAPK (mitogen-activated protein kinase).

2 cellular senescence and is activated by p38 mitogen-activated protein kinase.

3 it also inhibited the phosphorylation of p38 mitogen-activated protein kinase.

4 receptor also known as TrkA that upregulates mitogen-activated protein kinase.

5 ut increased cell invasion and activation of mitogen-activated protein kinases.

6 ovo missense variants in MAPK1, encoding the mitogen-activated protein kinase 1 (i.e., extracellular

7 l myenteric plexi and phosphorylation (p) of mitogen-activated protein kinase 1 (MAPK1) in the enteri

8 e P (SP), S100beta, GFAP, and phosphorylated mitogen-activated protein kinase 1 (pERK) were assessed

9 proteins, auxin stabilizes IAA33 protein via MITOGEN-ACTIVATED PROTEIN KINASE 14 (MPK14) and does not

10 Here, we report that mitogen-activated protein kinase 3 (MPK3) and MPK6 inter

11 Mitogen activated protein kinase 4 (MPK4) is a multifunc

12 e use Nicotiana attenuata plants silenced in mitogen-activated protein kinase 4 (irMPK4) - with low w

13 The strongest regulator of invasion was mitogen-activated protein kinase 4 (MAP4K4).

14 Previously, we demonstrated that Arabidopsis mitogen-activated protein kinase 6 (MPK6) and MPK3 play

15 elated prognostic proteins, particularly the mitogen-activated protein kinase 6, probable protein pho

16 samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptida

17 g22, PLC2-silenced plants maintain wild-type mitogen-activated protein kinase activation and PHI1, WR

18 nd extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase activation at the human

19 Mitogen-activated protein kinase activation by IL-8 has

20 Moreover, p38 mitogen-activated protein kinase activation emerges as a

21 for Ptpn6 in the negative regulation of p38 mitogen-activated protein kinase activation to control t

22 apoptosis signal-regulating kinase 1 and p38 mitogen-activated protein kinase) activation.

23 es G protein-coupled calcium ion signals and mitogen-activated protein kinase activity, and that its

24 Messenger RNA expression levels of p38 mitogen activated protein kinase and nuclear factor kapp

25 ntracellular signaling pathways, such as the mitogen-activated protein kinase and AKT signaling casca

26 We targeted the mitogen-activated protein kinase and phosphatidylinosito

27 h levels of reactive oxygen species in a p38 mitogen-activated protein kinase and phosphatidylinosito

28 e ability of pharmacologic inhibition of the mitogen-activated protein kinase and PI3'K pathways to i

29 via the gp130 signaling receptor, activating mitogen-activated protein kinase and signal transducer a

30 is revealed significant up-regulation of the mitogen-activated protein kinase and transforming growth

31 , oxidative stress, early phosphorylation of mitogen-activated protein kinases and Akt, and upregulat

32 were not affected in PAMP/DAMP activation of mitogen-activated protein kinases and expression of the

33 Activation of mitogen-activated protein kinases and NFkappaB signaling

34 of BRD4 is controlled, in part, by p38 MAPK (mitogen-activated protein kinase) and provide evidence o

35 of phosphorylated heat shock protein 27, p38 mitogen-activated protein kinase, and glycogen synthase

36 s extracellular signal-regulated kinase 1/2, mitogen-activated protein kinase, and Src, shown by immu

37 p38 mitogen-activated protein kinases are key mediators of e

38 lular signal-regulated kinase), JNK, and p38 mitogen-activated protein kinases as well as NFkappaB (n

39 ing a dual-specificity phosphatase targeting mitogen-activated protein kinases, as a type 2 diabetes

40 ulation in endothelial cells via JNK and p38 mitogen-activated protein kinase but not NF-kappaB.

41 identified OsPT8 as an interactor of a rice mitogen-activated protein kinase BWMK1, which is a regul

42 eltaPMN) neutrophils displayed increased p38 mitogen-activated protein kinase-dependent Ripk1-indepen

43 ial damage, epidermal growth factor receptor/mitogen-activated protein kinase (EGFR/MAPK) signalling

44 ion of extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK MAPK).

45 al-related kinase 1/2 (pERK1/2), a marker of mitogen-activated protein kinase-ERK signal transduction

46 ia extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK)-dependent

47 -X-C motif chemokine ligand 12 activates the mitogen-activated protein kinase extracellular-signal-re

48 ciated protein kinase 70 (ZAP-70), and three mitogen-activated protein kinases (extracellular signal-

49 otein expression that was attenuated by MEK (mitogen-activated protein kinase/extracellular signal-re

50 al growth factor receptor (EGFR), as EGFR or mitogen-activated protein kinase/extracellular signal-re

51 Subsequently, activation of a mitogen-activated protein kinase/extracellular signal-re

52 with the BRAF inhibitor vemurafenib and the mitogen-activated protein kinase/extracellular signal-re

53 ed that the rapidly accelerated fibrosarcoma/mitogen-activated protein kinase/extracellular signal-re

54 al stem-like (MSL) lineage downregulates the mitogen-activated protein kinase/extracellular signal-re

55 n N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and controls var

56 of CDKN2C and TP53, and mutations affecting mitogen-activated protein kinase genes.

57 beta-arrestin-dependent signaling responses, mitogen-activated protein kinase [i.e., extracellular si

58 preceded by decreased phosphorylation of p38 mitogen-activated protein kinase in HMuSC treated with C

59 eased proliferation and dysregulation of p38 mitogen-activated protein kinase in satellite cells comm

60 egulated protein kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase in T lymphocytes.

61 ed by the accumulation of phosphorylated p38 mitogen-activated protein kinase in the nucleus, which d

62 Mitogen-activated protein kinases, including c-Jun NH2-t

63 Conversely, after dual MET/mitogen-activated protein kinase inhibition, tumor growt

64 pretreatment with an oral small-molecule p38 mitogen-activated protein kinase inhibitor (Losmapimod;

65 vides a rationale for combining pan-ERBB and mitogen-activated protein kinase inhibitors as a therape

66 c target of rapamycin complex 1 (mTORC1) and mitogen-activated protein kinase interacting kinase (MNK

67 Finally, it reveals that mitogen-activated protein kinase interacting kinase-1 ha

68 tion-independent protein synthesis driven by mitogen-activated protein kinase interacting kinase-1, d

69 Targeting of the mitogen-activated protein kinase-interacting kinase (MNK

70 tion of lipid A limits the activation of the mitogen-activated protein kinase Jun N-terminal protein

71 tor of transcription (STAT) (ruxolitinib) or mitogen-activated protein kinase kinase (MEK) (trametini

72 ines had IC(50) values less than 7 nM to the mitogen-activated protein kinase kinase (MEK) 1/2 inhibi

73 mutational status, and response to B-Raf and mitogen-activated protein kinase kinase (MEK) inhibition

74 We show that the mitogen-activated protein kinase kinase (MEK) inhibitor

75 As validation, distinct mitogen-activated protein kinase kinase (MEK) inhibitors

76 therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors

77 Mitogen-activated protein kinase kinase (MEK) mutations

78 e/threonine-specific protein kinases (pRAF), mitogen-activated protein kinase kinase (pMEK), protein

79 A recently developed photoswitchable mitogen-activated protein kinase kinase 1 (MEK1) enzyme

80 Both VE-cadherin-silenced and mitogen-activated protein kinase kinase 1 (MEK1)-silence

81 ffector PI3K but instead require active MEK (mitogen-activated protein kinase kinase 1) signaling.

82 Hyperactivation of mitogen-activated protein kinase kinase 1/2 (MEK1/2), bu

83 ivated protein kinase kinase kinase 3)-MEK5 (mitogen-activated protein kinase kinase 5)-ERK5 (extrace

84 found REX1 to bind to the promoter region of mitogen-activated protein kinase kinase 6 (MKK6), thereb

85 mice with fibroblast-specific activation of mitogen-activated protein kinase kinase 6-p38 developed

86 ently described their potential in targeting mitogen-activated protein kinase kinase 7 (MKK7).

87 Focusing on mitogen-activated protein kinase kinase and Bcl-XL targe

88 gamma) intraperitoneally for 3 d or with the mitogen-activated protein kinase kinase inhibitor selume

89 2 depletion in ECs elicited increased MEKK3 (mitogen-activated protein kinase kinase kinase 3)-MEK5 (

90 restingly, we observed that knockdown of the mitogen-activated protein kinase kinase kinase 4 (MAP3K4

91 Among the differentially expressed kinases, mitogen-activated protein kinase kinase kinase kinase 4

92 Mitogen-activated protein kinase kinase kinase kinase-4

93 Mitogen-Activated Protein Kinase Kinase Kinase Kinase-4

94 r their mechanisms of action using selective mitogen-activated protein kinase kinase MEK1/2, MEK5, an

95 s pyruvate dehydrogenase kinase 1, Akt, Raf, mitogen-activated protein kinase kinase, and ERK1/2.

96 particular, we report synergistic effects of mitogen-activated protein kinase kinase, ribosomal S6 ki

97 Mitogen-activated protein kinase, kinase, kinase- 19 (MA

98 tical residues within the catalytic loops of mitogen-activated protein kinase kinases (MAPKKs).

99 Although LF is known to cleave mitogen-activated protein kinase kinases (MEKs/MKKs) and

100 -in-class von Hippel-Lindau (VHL)-recruiting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2

101 screen identified multiple components of the mitogen activated protein kinase (MAPK) pathway enhancin

102 extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) pathway.

103 nical nuclear factor kappa B (NF-kappaB) and mitogen activated protein kinase (MAPK) pathways have be

104 ncers contain genetic alterations within the Mitogen Activated Protein Kinase (MAPK) signaling networ

105 In this study, we identify a complete mitogen-activated protein kinase (MAPK or MPK) cascade,

106 mune signaling, including phosphorylation of mitogen-activated protein kinase (MAPK) 3 (MPK3) and MPK

107 MADD, the mitogen-activated protein kinase (MAPK) activating death

108 ls converging at the MOR promoter, involving mitogen-activated protein kinase (MAPK) activation and m

109 ly led to decrease in negative regulators of mitogen-activated protein kinase (MAPK) activation, incl

110 D family members 2, 3, and 4 (SMAD2/3/4) and mitogen-activated protein kinase (MAPK) activities, whic

111 was caused by an elevation in macrophage p38 mitogen-activated protein kinase (MAPK) activity.

112 through elevated and sustained activation of mitogen-activated protein kinase (MAPK) and AKT.

113 The expression of mitogen-activated protein kinase (MAPK) and endothelial

114 species (ROS) production, and activated p38 mitogen-activated protein kinase (MAPK) and p53.

115 Mutations at both interfaces interfered with mitogen-activated protein kinase (MAPK) and phosphoinosi

116 d proliferative (PRO) phenotypes linked with mitogen-activated protein kinase (MAPK) and signal trans

117 used it to analyze a set of D-motif peptide-mitogen-activated protein kinase (MAPK) associations to

118 Activation of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal

119 e to mating pheromone activates a prototypic mitogen-activated protein kinase (MAPK) cascade and trig

120 idopsis, an extremely functionally redundant mitogen-activated protein kinase (MAPK) cascade is requi

121 ERK3 is an atypical mitogen-activated protein kinase (MAPK) containing an S-

122 The protein p38 mitogen-activated protein kinase (MAPK) delta isoform (p

123 reatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PK

124 daptors to regulate AT1R internalization and mitogen-activated protein kinase (MAPK) ERK1/2 activatio

125 increased levels of total and phosphorylated mitogen-activated protein kinase (MAPK) family members s

126 e a conserved feature of some members of the mitogen-activated protein kinase (MAPK) family.

127 Previous studies showed that activation of mitogen-activated protein kinase (MAPK) in diabetes prom

128 KO mice with enhanced phosphorylation of p38 mitogen-activated protein kinase (MAPK) in podocytes.

129 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in Saccharomyces

130 Smk1 is a meiosis-specific mitogen-activated protein kinase (MAPK) in yeast that co

131 The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was c

132 ype I priming, or the combination of Src and mitogen-activated protein kinase (MAPK) inhibitors, whic

133 Mitogen-activated protein kinase (MAPK) interacting kina

134 artially rescued by constitutively activated mitogen-activated protein kinase (MAPK) kinase kinase YO

135 Microbial pathogens often target the host mitogen-activated protein kinase (MAPK) network to suppr

136 paired the activity of key components of the mitogen-activated protein kinase (MAPK) pathway (p38 and

137 WASP-deficient lymphoma showed increased mitogen-activated protein kinase (MAPK) pathway activati

138 ling pathway, beta-arrestin recruitment, and mitogen-activated protein kinase (MAPK) pathway activati

139 brane (PM) correlates with activation of the mitogen-activated protein kinase (MAPK) pathway and subs

140 Mitogen-activated protein kinase (MAPK) pathway antagoni

141 hodiesterase inhibitor and also modifies the mitogen-activated protein kinase (MAPK) pathway by downr

142 ptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controll

143 arget the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led

144 "paradoxical" upregulation of the downstream mitogen-activated protein kinase (MAPK) pathway in cance

145 TGF-beta depends on RAS and mitogen-activated protein kinase (MAPK) pathway inputs f

146 The mitogen-activated protein kinase (MAPK) pathway is a key

147 Identifying additional mitogen-activated protein kinase (MAPK) pathway regulato

148 nsition (EMT), mediated, in part, by the p38 mitogen-activated protein kinase (MAPK) pathway respondi

149 Signaling analysis indicated decreased mitogen-activated protein kinase (MAPK) pathway signalin

150 ic cells (DCs) with constitutively activated mitogen-activated protein kinase (MAPK) pathway signalin

151 that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway(1,2).

152 BRAF, a kinase in the mitogen-activated protein kinase (MAPK) pathway, is muta

153 umor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway.

154 ic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway.

155 or (BDNF)-activated enzyme downstream of the mitogen-activated protein kinase (MAPK) pathway.

156 tivated kinase Ste20p, Cdc42p also regulates mitogen-activated protein kinase (MAPK) pathways (mating

157 Mitogen-activated protein kinase (MAPK) pathways are con

158 Cellular signaling pathways, including the mitogen-activated protein kinase (MAPK) pathways, are re

159 dependent on the activation of the NF-kB and mitogen-activated protein kinase (MAPK) pathways, which

160 pattern recognition receptors activates the mitogen-activated protein kinase (MAPK) pathways, which

161 athways, whereas FGFR2b relied on downstream mitogen-activated protein kinase (MAPK) pathways.

162 nhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) pathways.

163 The mitogen-activated protein kinase (MAPK) phosphatases (MK

164 These express a mitogen-activated protein kinase (MAPK) programme that w

165 ll fusion, is mediated by Gbetagamma and the mitogen-activated protein kinase (MAPK) scaffold protein

166 Mitogen-activated protein kinase (MAPK) scaffold protein

167 In the absence of RASA1, dysregulated Ras mitogen-activated protein kinase (MAPK) signal transduct

168 PF included extracellular matrix remodeling, Mitogen-activated protein kinase (MAPK) signaling and AL

169 strains, we show that candidalysin activates mitogen-activated protein kinase (MAPK) signaling and ch

170 AS, and BRAF mutations which activate p44/42 mitogen-activated protein kinase (MAPK) signaling are fo

171 orted that kinase-dead BRAF variants amplify mitogen-activated protein kinase (MAPK) signaling by dim

172 to interact with both survival and apoptotic mitogen-activated protein kinase (MAPK) signaling cascad

173 ated calcium channel Cacophony (Cac) and the mitogen-activated protein kinase (MAPK) signaling cascad

174 ed by PTPN11, plays an essential role in RAS-mitogen-activated protein kinase (MAPK) signaling during

175 PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may re

176 sor that is differentially regulated through mitogen-activated protein kinase (MAPK) signaling or gen

177 4b to act as a negative regulator of the RAS/mitogen-activated protein kinase (MAPK) signaling pathwa

178 S. cerevisiae plays crucial roles in various mitogen-activated protein kinase (MAPK) signaling pathwa

179 At the molecular level, besides the mitogen-activated protein kinase (MAPK) signaling pathwa

180 tein, VopA, has potent inhibitory effects on mitogen-activated protein kinase (MAPK) signaling pathwa

181 ally, inhibition of the PI3K, but not of the mitogen-activated protein kinase (MAPK) signaling pathwa

182 AF gene fusions that aberrantly activate the mitogen-activated protein kinase (MAPK) signaling pathwa

183 and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) signaling pathwa

184 kinase, p38, and c-Jun amino-terminal kinase mitogen-activated protein kinase (MAPK) signaling to eli

185 Elevated Pi activates mitogen-activated protein kinase (MAPK) signaling, encom

186 of RAF proto-oncogene, Ser/Thr kinase (Raf)-mitogen-activated protein kinase (MAPK) signaling, induc

187 c) Homology Phosphatase 2 (Shp2) to activate Mitogen-Activated Protein Kinase (MAPK) signaling, which

188 of Bmf expression, predominantly via p44/42 mitogen-activated protein kinase (MAPK) signaling.

189 cules, thus suppressing Raf-1 activation and mitogen-activated protein kinase (MAPK) signaling.

190 with genes implicated in focal adhesion and mitogen-activated protein kinase (MAPK) signaling.

191 1 (CK1) sites Cx43(S325A/328Y/330A), and the mitogen-activated protein kinase (MAPK) sites Cx43(S255/

192 gh autophosphorylation and activation of p38 mitogen-activated protein kinase (MAPK) via a non-canoni

193 identified NF-kappaB activator 1 (Act1), p38 mitogen-activated protein kinase (MAPK), Jun NH2-termina

194 ake of bacteria, which required PDK1, and of mitogen-activated protein kinase (MAPK)- and nuclear fac

195 its rapid basal turnover in neurons and that mitogen-activated protein kinase (MAPK)-dependent phosph

196 kinase (IKK), c-jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK)-extracellular re

197 l GTPases, p21-activated kinase, and the p38 mitogen-activated protein kinase (MAPK)-MAPK-activated p

198 of all pathogenic non-Dsg AuAbs involved p38 mitogen-activated protein kinase (MAPK)-mediated phospho

199 which transcription factors are released by mitogen-activated protein kinase (MAPK)-stimulated acety

200 lung injury is blunted by inhibitors of p38 mitogen-activated protein kinase (MAPK).

201 fungi that regulates the downstream HOG/p38 mitogen-activated protein kinase (MAPK).

202 Inhibition of MEK (mitogen-activated protein kinase (MAPK)/ERK kinase) afte

203 Cystic kidneys showed increased mitogen-activated protein kinase (MAPK)/extracellular si

204 (PI3K)/Akt serine/threonine kinase (Akt) and mitogen-activated protein kinase (MAPK)/extracellular si

205 On the basis of our previous work on mitogen-activated protein kinase (MAPK)/extracellular si

206 an extremely potent allosteric inhibitor of mitogen-activated protein kinase (MAPK)/extracellular-si

207 f the JCI, Yokota et al. reveal that the p38 mitogen-activated protein kinase (MAPK)/IRE1alpha/XBP1 a

208 cular chondrocytes via the inhibition of p38 mitogen-activated protein kinases (MAPK) and increasing

209 transcription factors are phosphorylated by mitogen-activated protein kinases (MAPK) in their transa

210 mapping revealed the involvement of K-RAS in mitogen-activated protein kinases (MAPK) pathway.

211 Mitogen-activated protein kinases (MAPK) such as p38 and

212 ar signal-regulated kinase 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPK), leading to unc

213 relatively rare member of the JNK family of mitogen-activated protein kinases (MAPK), phosphorylates

214 d kinase (ERK)/C-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPK)] were assessed

215 biquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physio

216 -inflammatory pathways such as NF-kappaB and mitogen activated protein kinases (MAPKs), and the subse

217 MAP3K4 functions upstream of the p38 and JNK mitogen activated protein kinases (MAPKs).

218 ral detail on docking interactions involving mitogen-activated protein kinases (MAPKs) and their subs

219 KIM-PTPs bind and dephosphorylate mitogen-activated protein kinases (MAPKs) and thereby cr

220 The molecular actions of mitogen-activated protein kinases (MAPKs) are ultimately

221 s diverse kinase pathways, which include the mitogen-activated protein kinases (MAPKs) ERK and p38, t

222 Mitogen-activated protein kinases (MAPKs) form important

223 Cellular mitogen-activated protein kinases (MAPKs) have been show

224 The catalytic activity of mitogen-activated protein kinases (MAPKs) is dynamically

225 t/MKP-1 pathway results in the inhibition of mitogen-activated protein kinases (MAPKs) JNK and p38.

226 Mitogen-activated protein kinases (MAPKs) mediate numero

227 we show that the rapid activation of clade-A mitogen-activated protein kinases (MAPKs) MPK3 and MPK6

228 Mitogen-activated protein kinases (MAPKs) regulate essen

229 Of note, two mitogen-activated protein kinases (MAPKs), extracellular

230 Two flg22-responsive mitogen-activated protein kinases (MAPKs), MPK3 and MPK6

231 (DUSP1), an endogenous negative regulator of mitogen-activated protein kinases (MAPKs), resulting in

232 some are under transcriptional regulation by mitogen-activated protein kinases (MAPKs).

233 n of oncogenic Ras(V12) activates downstream mitogen-activated protein kinase (MEK-ERK) signaling to

234 uclear cells of sepsis patients, whereas p38 mitogen activated protein kinase messenger RNA was up-re

235 Mitogen-activated protein kinase (MPK) cascades are cons

236 nd ROS signals compromised the activation of mitogen-activated protein kinases (MPKs) 1/2 in leaves.

237 uce new KRAS(G12C) in response to suppressed mitogen-activated protein kinase output.

238 sion of sequestosome 1 (p62) and phospho-p38 mitogen-activated protein kinases (p-p38) showed a signi

239 Furthermore, phosphorylation of the mitogen-activated protein kinase p38 was enhanced and ph

240 icity phosphatase 1, impairs the activity of mitogen-activated protein kinase p38, increases the acti

241 , which dephosphorylates and inactivates the mitogen-activated protein kinases p38 and Jun N-terminal

242 s upregulated with aging, which enhances p38 mitogen-activated protein kinase (p38 MAPK) activation a

243 Increases in the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) and decrease

244 NASH development and the involvement of p38 mitogen-activated protein kinase (p38) activated by neut

245 CyTP genes is mediated by the conserved p38 mitogen-activated protein kinase (p38-MAPK) pathway.

246 Signal transduction pathways mediated by p38 mitogen-activated protein kinase (p38MAPK), extracellula

247 rticularly, we found that alterations of the mitogen-activated protein kinase pathway (KRAS and NRAS

248 Finally, we demonstrate mitogen-activated protein kinase pathway activation and

249 ward beta-arrestin recruitment and increased mitogen-activated protein kinase pathway activation.

250 llular signal-regulated protein kinase (ERK) mitogen-activated protein kinase pathway and that ERK in

251 ted, at least in part, via activation of the mitogen-activated protein kinase pathway following calci

252 M) in 60%, and phosphatidylinositol 3-kinase/mitogen-activated protein kinase pathway genes (eg, ERBB

253 breast cancer, and inhibitors of the RAS/RAF/mitogen-activated protein kinase pathway in RAS-mutant c

254 phosphorylation of focal adhesion kinase and mitogen-activated protein kinase pathway leading to enha

255 th the extracellular signal-regulated kinase mitogen-activated protein kinase pathway that provides a

256 ectively, these findings demonstrate the ERK mitogen-activated protein kinase pathway to be integrall

257 ibed the paradoxical triggering of the human mitogen-activated protein kinase pathway when a small-mo

258 extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase pathway, consistent wit

259 K (RAS-extracellular signal-regulated kinase/mitogen-activated protein kinase) pathway integrates gro

260 ransducer and activator of transcription and mitogen-activated protein kinase pathways to regulate ce

261 y, pyrin domain-containing-3, and downstream mitogen-activated protein kinase pathways.

262 enotype was characterized by upregulation of mitogen-activated protein kinase pathways.

263 lear factor-kappaB, as well as activation of mitogen-activated protein kinases pathways.

264 In neutrophils of sepsis patients, mitogen activated protein kinase phosphatase-1 messenger

265 sis factor-alpha-induced protein 3 (A20) and mitogen activated protein kinase phosphatase-1 were dete

266 ofin (ARN), an antirheumatic drug, to induce mitogen-activated protein kinase phosphatase (MKP)-1 exp

267 bacterium tuberculosis (Mtb) by facilitating mitogen-activated protein kinase phosphatase 1 (MKP-1)-d

268 lular signal-regulated kinase 1/2, increased mitogen-activated protein kinase phosphatase 1 expressio

269 ed with a pharmacological agent that induces mitogen-activated protein kinase phosphatase have potent

270 past several years has elucidated a role for mitogen-activated protein kinase phosphatase to regulate

271 The Erk mitogen-activated protein kinase plays diverse roles in

272 2, PtrHAB13 and PtrHAB14 interacted with the mitogen-activated protein kinase protein PtrMPK7.

273 tly driven by genetic alterations in the RAS-mitogen-activated protein kinase (RAS/MAPK) pathway yet

274 hed in synaptic function and converge on Ras/mitogen-activated protein kinase (Ras/MAPK) signaling.

275 st transdifferentiation by activation of p38 mitogen-activated protein kinases resulting in upregulat

276 otein kinase C, cyclin-dependent kinase, and mitogen-activated protein kinase showed increased phosph

277 nger NHFs, PDAC cells exhibited increases in mitogen-activated protein kinase signaling and cellular

278 E-cadherin/epidermal growth factor receptor/mitogen-activated protein kinase signaling axis.

279 folded protein response, glycolysis, and the mitogen-activated protein kinase signaling cascade.

280 Whereas suppressing or enhancing Ras/mitogen-activated protein kinase signaling changed how s

281 d causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity

282 e renin-angiotensin system in the kidney and mitogen-activated protein kinase signaling in the heart.

283 terations in genes whose products are in the mitogen-activated protein kinase signaling pathway and a

284 g mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway.

285 roteins in receptor tyrosine kinase, RAS, or mitogen-activated protein kinase signaling pathways.

286 se 4 (MAP3K4) gene, which contributes to p38 mitogen-activated protein kinase signaling, sensitized c

287 ed with wild-type mice, along with decreased mitogen-activated protein kinase signaling, tumor angiog

288 suppression of the inflammatory response and mitogen-activated protein kinase signaling.

289 extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase signaling.

290 cytoskeletal structures, and hyperactivated mitogen-activated protein kinase signaling.

291 ptation and stress tolerance, and in several mitogen-activated protein kinases signaling pathways inc

292 ion of 101 gene transcripts, including MAPK (mitogen-activated protein kinase) signaling targets, HOP

293 ignalling, cell cycle regulatory signalling, mitogen-activated protein kinase signalling and pathways

294 nsducer and activator of transcription 3 and mitogen-activated protein kinase signalling in an inocul

295 In contrast, mitogen-activated protein kinase, Src tyrosine kinase, a

296 HAI1 or by HAI1-regulated kinases including mitogen-activated protein kinases, sucrose non-fermentin

297 rhabditis elegans, we implicate the atypical mitogen activated protein kinase, SWIP-13, in DAT regula

298 of reactive oxygen species and activation of mitogen-activated protein kinases upon exposure to flg22

299 s lost by suppressing the activity of Ras or mitogen-activated protein kinase, whereas the overexpres

300 diverse modes of injury converge on p38alpha mitogen-activated protein kinase within the fibroblast t